Cristal Therapeutics starts clinical Phase I trial with nanomedicine CriPec docetaxel in patients with solid tumours
![](/46/pdcnewsitem/03/63/00/cristal.jpg)
The CriPec platform allows for the rational design of custom-made nanomedicines for controlled release of the drug at the desired site of action resulting in an improved efficacy and tolerability.
Cristal Therapeutics has announced the recent start of a clinical Phase I trial with its lead candidate CriPec docetaxel in patients with solid tumours. For this trial, patients are being recruited in two clinical centres in The Netherlands and in Belgium. The first trial data will be available in the course of Q2 2016.
Cristal Therapeutics has developed a pioneering approach to transform existing drugs against cancer, like docetaxel, and other diseases, into tailor-made nanoparticles via its proprietary polymeric technology, registered as CriPec. The CriPec platform allows for the rational design of custom-made nanomedicines for controlled release of the drug at the desired site of action resulting in an improved efficacy and tolerability.
CriPec docetaxel is Cristal Therapeutics’ lead candidate in development and represents a novel treatment approach of solid tumours. CriPec docetaxel successfully passed various pre-clinical studies, demonstrating a significantly improved safety and tolerability profile. Current docetaxel-containing products often have limited efficacy, and prolongation of survival comes with a high incidence of adverse events. This imposes major limitations on the current therapy. CriPec nanoparticles accumulate in tumour tissue, resulting in a significantly higher CriPec docetaxel exposure of the tumour, thereby overcoming drawbacks of conventional docetaxel therapies
.Joost Holthuis, CEO of Cristal Therapeutics says: “We are very excited about the start of the clinical Phase I trial. The outcome of our pre-clinical program has been very encouraging and highlights the clinical potential of CriPec docetaxel. We are looking forward to advance this compound quickly into the Phase I- Part II trial that is expected to start next year. If successful, this will enable chemotherapy to be applied more effectively, with fewer adverse events, which is in the interest of patients with solid tumours worldwide.”
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance